Lozza G, Conti A, Ongini E, Monopoli A
Schering-Plough Research Institute, Milan, Italy.
Pharmacol Res. 1997 Jan;35(1):57-64. doi: 10.1006/phrs.1996.0120.
It has been postulated that the adenosine A1 receptor subtype, but also A2a receptors, are involved in mediating the beneficial properties of adenosine during ischemia and reperfusion. We investigated the effects of the selective A1 adenosine receptor agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), the selective A2A adenosine receptor agonists, 2-[p-(2-carboxyethyl)phenetylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21680), 2-hexynyl-5'-N-ethylcarboxamidoadenosine (2HE-NECA), and the non selective agonist, 5'-N-ethylcarboxamidoadenosine (NECA), on ischemia-reperfusion injury in Langendorff-perfused rat hearts. Global ischemia was induced for 15 min in paced hearts followed by 60 min reperfusion. Control hearts developed left ventricular dysfunction, as indicated by the increase in end diastolic pressure to 40.8 +/- 5.1 vs 5.9 +/- 1.0 mm Hg baseline, and in coronary perfusion pressure to 57.6 +/- 8.4 vs 28.8 +/- 2.2 mm Hg before ischemia. After 15 min of reperfusion, ventricular function (LVDP) recovered by 83%, but creatine kinase levels were still significantly increased (294 +/- 55 IUl(-1) vs basal), indicating the occurrence of myocardial injury. All adenosine agonists added to the perfusion medium 15 min prior to ischemia exerted protective effects against myocardial dysfunction and reperfusion injury. Thus, 2HE-NECA (100 nM), CGS 21680 (10 nM), CCPA (3 nM) and NECA (100 nM) significantly (P < 0.05) decreased end diastolic pressure by 50-75% as compared with the control group. Similarly, all compounds significantly (P < 0.05) reduced coronary perfusion pressure by 30-45% vs control. For all drugs, recovery of LVDP occurred immediately after restoration of coronary flow. At 15-min reperfusion the adenosine agonists decreased myocardial creatine kinase release by 80-95% (P < 0.05 vs control). These findings indicate that both A1 and A2A adenosine receptors are involved in protecting the myocardium against ischemia and reperfusion in isolated rat heart, even if through different mechanisms.
据推测,腺苷A1受体亚型以及A2a受体均参与介导腺苷在缺血和再灌注过程中的有益特性。我们研究了选择性A1腺苷受体激动剂2-氯-N6-环戊基腺苷(CCPA)、选择性A2A腺苷受体激动剂2-[对-(2-羧乙基)苯乙氨基]-5'-N-乙基甲酰胺基腺苷(CGS 21680)、2-己炔基-5'-N-乙基甲酰胺基腺苷(2HE-NECA)以及非选择性激动剂5'-N-乙基甲酰胺基腺苷(NECA)对Langendorff灌注大鼠心脏缺血再灌注损伤的影响。在起搏心脏中诱导全心缺血15分钟,随后进行60分钟再灌注。对照心脏出现左心室功能障碍,表现为舒张末期压力从基线的5.9±1.0 mmHg增加到40.8±5.1 mmHg,冠状动脉灌注压力从缺血前的28.8±2.2 mmHg增加到57.6±8.4 mmHg。再灌注15分钟后,心室功能(左心室发展压)恢复了83%,但肌酸激酶水平仍显著升高(294±55 IU l(-1) 对比基础值),表明发生了心肌损伤。在缺血前15分钟添加到灌注培养基中的所有腺苷激动剂均对心肌功能障碍和再灌注损伤发挥了保护作用。因此,与对照组相比,2HE-NECA(100 nM)、CGS 21680(10 nM)、CCPA(3 nM)和NECA(100 nM)显著(P<0.05)使舒张末期压力降低了50 - 75%。同样,与对照组相比,所有化合物均显著(P<0.05)使冠状动脉灌注压力降低了30 - 45%。对于所有药物,冠状动脉血流恢复后左心室发展压立即恢复。在再灌注15分钟时,腺苷激动剂使心肌肌酸激酶释放降低了80 - 95%(与对照组相比P<0.05)。这些发现表明,A1和A2A腺苷受体均参与保护离体大鼠心脏免受缺血和再灌注损伤,即使是通过不同机制。